ICD-10 R10.20 is officially defined as "Pelvic and perineal pain unspecified side." code R10.20 is referenced in 13 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, Regence BlueShield, and 3 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R10.20 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Multiple medical policies are being updated with changes to prior authorization requirements, covered diagnosis codes, and billing procedures across various specialties. Key changes include removal of prior authorization for several CPT codes, addition of new ICD-10 codes for breast cancer-related services, and updates to genetic testing coverage criteria.
Multiple policy updates are rolling out between February-April 2026, including InterQual criteria changes for molecular diagnostics and procedures, fertility coverage modifications, removal of prior authorization for several genetic testing and continuous glucose monitoring codes, and updated diagnosis code lists for various services.
Effective November 1, 2026, site of care medical necessity reviews apply to the listed surgical procedures only when they are performed in an outpatient hospital setting. Use of a hospital outpatient department instead of an ambulatory surgery center or physician office may be considered medically necessary when one or more listed criteria are met, such as no geographically accessible in-network ASC that has the necessary equipment, a procedure that requires discontinuing medications that necessitate inpatient monitoring or treatment, ASA Physical Status III or higher, or a BMI over 40. Hospital outpatient use is considered not medically necessary when the criteria are not met.
Effective July 1, 2026, hysterectomy may be considered medically necessary when the policy criteria are met for abnormal uterine bleeding, pelvic pain, endometriosis, chronic pelvic inflammatory disease, pelvic adhesive disease, pelvic venous congestion, adenomyosis, cervical intraepithelial neoplasia, or leiomyoma. Hysterectomy for these indications is considered not medically necessary when the criteria are not met, and clinical documentation supporting the criteria is required.
Independence Blue Cross updated ICD-10 diagnosis codes for Pelvic Floor Therapy services under policy 00.03.06g, effective 10/01/2025. The broad code R10.2 (abdominal pain) was replaced with five more specific subcodes (R10.20, R10.21, R10.22, R10.23, R10.24), and hand therapy diagnosis codes on Attachment A2 (S62.90XA, S62.90XB, S62.91XA, S62.91XB, S62.92XA, S62.92XB) received narrative revisions. Billing teams must update their systems to recognize only the new specific codes for claims reimbursement above capitation for HMO/HMO-POS members.
Aetna considers TENS units medically necessary durable medical equipment when used as an adjunct or alternative to drugs for acute post-operative pain in the first 30 days after surgery, or for certain chronic, intractable pain not adequately responsive to other methods. Peripherally implanted nerve stimulators are considered medically necessary for intractable neuropathic pain when all listed criteria are met. Percutaneous electrical nerve stimulation is considered medically necessary for chronic low back pain secondary to degenerative disc disease for up to a 30-day period within a multi-modality rehabilitation program, and for diabetic neuropathy or neuropathic pain that has not responded to listed medications. Many other electrical stimulation devices and indications are listed as experimental, investigational, or unproven.
Aetna considers cognitive behavioral therapy and psychotherapy medically necessary for female sexual dysfunction, and considers pelvic floor physical therapy for genito-pelvic pain disorders medically necessary as well. Psychotherapy codes 90832, 90833, 90834, 90836, 90837 and 90838, plus code 97110, are covered when the selection criteria are met. Bibliotherapy, biothesiometry, oxytocin, MDMA, hyaluronic acid, endo-vaginal and vulvar rejuvenation laser, radiofrequency ablation and radiofrequency thermal therapy, platelet-rich plasma and fibrin injections, percutaneous tibial nerve stimulation, sacral neuromodulation, transcranial direct current stimulation, vaginal electrical stimulation, female erectile devices, and stem cell, gene and growth factor therapies are considered experimental, investigational or unproven because of insufficient evidence. Aetna does not cover vibrators, which do not meet its contractual definition of covered durable medical equipment.
CalViva Health (Health Net's Medi-Cal plan in California) updated seven clinical policies, with the source stating they were approved for and effective in August 2026, so those changes are already in effect. The changes add or delete diagnosis and CPT codes for urodynamic testing, genitourinary and GI pathogen panels, narrow the criteria for selective nerve root blocks and epidural steroid injections, and tighten documentation rules for applied behavior analysis services.
Community Health Plan of Imperial Valley (a Medi-Cal plan in Imperial County, California) updated seven clinical policies, with the source stating they were approved for and effective in August 2026, so those changes are already in effect. The changes add or delete diagnosis and CPT codes for urodynamic testing, genitourinary and GI pathogen panels, narrow the criteria for selective nerve root blocks and epidural steroid injections, and tighten documentation rules for applied behavior analysis services.
Health Net's August 2026 clinical policy update changes medical necessity criteria and code lists in several policies. The biggest change is that selective nerve root blocks are now for diagnostic purposes only, with therapeutic indications removed, and the notice also updates ICD-10 and CPT lists for urodynamic testing, GI pathogen panels, vaginitis testing and vagus nerve stimulation. The notice gives no day-level effective date beyond August 2026, so treat these changes as already in effect and check the full policies in the Provider Library.
Aetna Clinical Policy Bulletin 0863 covers nerve blocks and lists which ones it considers medically necessary. Covered uses include adductor canal, femoral, fascia iliaca, erector spinae plane and transversus abdominis plane blocks for post-operative pain after specific surgeries, and celiac plexus block for cancer pain, while peripheral nerve blocks for chronic pain are covered only as an active component of a comprehensive pain management program. Blocks listed as experimental and investigational include genicular nerve blocks and peripheral nerve blocks used as the sole treatment for chronic non-malignant pain, because the effectiveness of these approaches has not been established.
Aetna considers cognitive behavioral therapy or psychotherapy and pelvic floor physical therapy for genito-pelvic pain disorders medically necessary for female sexual dysfunction (FSD). Aetna considers bibliotherapy, biothesiometry, oxytocin, MDMA, percutaneous tibial nerve stimulation, sacral neuromodulation, vaginal electrical stimulation, female erectile devices, and several laser, radiofrequency, injection and regenerative therapies experimental, investigational or unproven for FSD because of insufficient evidence. Aetna does not cover vibrators because they do not meet its contractual definition of covered durable medical equipment, and some Aetna plans exclude drugs or supplies for sexual dysfunction or inadequacy.
Aetna's Microwave Thermotherapy policy (CPB 0682) was reviewed on 2026-10-26, and the source does not state what changed or give a new effective date. It covers microwave thermotherapy as medically necessary only for T1 renal lesions, medically inoperable non-small cell lung cancer lesions under 3 cm, and hepatocellular carcinoma tumors of 3 cm or less, and it lists many other uses (such as breast, pancreatic, bladder, and chronic pain indications) as experimental, investigational or unproven.
Watch R10.20
Get one email when a payer policy names R10.20, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.